• Affiliate Professor, Global Health
  • Affiliate Professor, Medicine - Medical Genetics
  • Vice President, IDRI
  • CEO, PAI Life Sciences
  • CEO, Compliment Corp.

Seattle, WA 98102
United States

Phone Number: 
Select from the following:

Darrick Carter is a biochemist/biophysicist with over
20 years of biotech experience. He founded five companies beginning with an internet startup. At Corixa Corp., he led a new tuberculosis vaccine into human trials. He started Protein AI, a bioinformatics company using proprietary artificial neural nets. He helped spin out Dharma Therapeutics a specialty pharma company for drug delivery. Next, he co-founded a company improving cancer outcomes, Compliment Corp. He is inventor on over 120 patents and applications and CEO of PAI Life Sciences as well as being VP / Adjuvant Technologies at IDRI.

  • PhD (Oregon Health & Science University)
  • BS (Oregon State University)
Country Affiliations 
  • German
Health Topics 
  • Biodefense Infectious Diseases
  • Cancer
  • Cervical Cancer
  • Drug and Vaccine Development
  • Ebola
  • Hepatitis
  • Immunizations
  • Infectious Diseases
  • Infectious Diseases (other than STDs)
  • Influenza
  • Informatics
  • Innate Immunity
  • Leishmaniasis
  • Malaria
  • Molecular Immunology
  • Neglected Diseases, Tropical Medicine (incl. Parasites)
  • TB
  • Viruses

Orr MT, Khandhar AP, Seydoux E, Liang H, Gage E, Mikasa T, Beebe EL, Rintala ND, Persson KH, Ahniyaz A, Carter D, Reed SG, Fox CB. “Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology”. npj Vaccines. 2019;4(1):1. doi: 10.1038/s41541-018-0094-0.

Carter D, van Hoeven N, Baldwin S, Levin Y, Kochba E, Magill A, Charland N, Landry N, Nu K, Frevol A, Ashman J, Sagawa ZK, Beckmann AM, Reed SG. The adjuvant GLA-AF enhances human intradermal vaccine responses. Science - Advances. 2018;4(9). doi: 10.1126/sciadv.aas9930.

Seydoux E, Liang H, Cauwelaert ND, Archer M, Rintala ND, Kramer R, Carter D, Fox CB, Orr MT. Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways to Promote Potent Adaptive Immune Responses. J. of Immunology May 16, 2018, ji1701604; DOI: 10.4049/jimmunol.1701604

Van Hoeven N, Fox CB, Granger B, Evers T, Joshi SW, Nana GI, Evans SC, Lin S, Liang H, Liang L, Nakajima R, Felgner PL, Bowen RA, Marlenee N, Hartwig A, Baldwin SL, Coler RN, Tomai M, Elvecrog J, Reed SG, Carter D. “A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines” Nature – Scientific Reports 2017 Apr 21;7:46426. doi: 10.1038/srep46426. PMID: 28429728; PubMed Central PMCID: PMC5399443.

Carter D, Fox CB, Day TA, Guderian JA, Liang H, Rolf T, Vergara J, Sagawa ZK, Ireton G, Orr MT, Desbien A, Duthie MS, Coler RN, Reed SG. A structure-function approach to optimizing TLR4 ligands for human vaccines. Nature: Clin Trans Immunol. 2016;5:e108. doi: 10.1038/cti.2016.63.